Travere Therapeutics Inc. Common Stock vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.94 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 15× Travere Therapeutics Inc. Common Stock's market cap, and Vanguard Sht-Term Inflation-Protected Sec Idx ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 92 Days on average.
| TVTX | VTIP | |
|---|---|---|
Market Cap | $4.88B | $73.20B |
Volume | 1,668,577 | 2,410,205 |
Sector | Health | — |
52-Week High | $67.52 | $50.46 |
52-Week Low | $26.79 | $48.38 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $5.01B | — |
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
VTIP, a Vanguard short-term inflation-protected securities ETF, trades at $48.46, down 0.06% on the day. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators are neutral. The fund focuses on short-duration TIPS to hedge inflation with minimal interest-rate risk, attracting institutional interest as seen in recent filings. News highlights its role in protecting against inflation spikes and Fed rate hikes.
The outlook for VTIP is supported by persistent inflation and high real yields, offering a defensive allocation. Risks include interest rate volatility and potential underperformance if inflation recedes. Institutional accumulation suggests confidence, but investors should weigh the fund's low sensitivity against broader bond market shifts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →